Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: KEGG:D01453 (
caffeine
)
21,611
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The main polycyclic aromatic hydrocarbon-inducible
cytochrome P450
was studied in lung tissue from 57 lung cancer patients by immunohistochemistry, using a monoclonal antibody (1-7-1) that recognizes P450IA1 and P450IA2 isozymes. The intensity of immunostaining was compared with the pulmonary activity of a P450IA1-dependent enzyme, aryl hydrocarbon hydroxylase (AHH), and with P450IA2-related metabolic activity estimated from the ratio of
caffeine
metabolites in urine. Immunostaining was not observed in peripheral lung tissue of nonsmokers or ex-smokers but was seen in the bronchiolar and alveolar epithelium of all patients who were smokers and had a peripheral carcinoma (16/16) and of 60% (10/17) of those who had a bronchial carcinoma. AHH activity was positively related to the intensity of immunostaining, and an almost 2-fold increase due to smoking was detected in the ratios of
caffeine
metabolites. These results demonstrate that tobacco smoke induces P450IA1 in the lung and probably P450IA2 in the liver, and suggest a role for certain metabolic phenotypes of P450IA1 in peripheral pulmonary carcinoma.
...
PMID:Immunohistochemical detection of pulmonary cytochrome P450IA and metabolic activities associated with P450IA1 and P450IA2 isozymes in lung cancer patients. 133 24
Kinetics of the 2- and 4-hydroxylations of estradiol (E2) by human liver microsomal samples were studied to determine the major P450 isoform involved in these endogenous reactions. Thirty human liver microsomal samples were analysed. Metabolism of 25 microM [14C]E2 produced 2-hydroxy and 4-hydroxy derivatives with a ratio of 3.2 +/- 1.5 and a great inter-individual variation. Kinetic analysis of the 2- and 4-hydroxylations of E2 exhibited a curvilinear double reciprocal plot with an apparent Km of 15 microM. Further experiments demonstrated that alpha-naphthoflavone, testosterone and progesterone increased the 2-hydroxylation activity, suggesting the involvement of a substrate activation mechanism. These two hydroxylations of E2 were shown to be catalysed by
cytochrome P450
with an apparent dissociation constant Ks of 0.8 microM. These 2- and 4-hydroxylations inter-correlated significantly (r = 0.93; N = 30). The 2-hydroxylation of E2 correlated with four monooxygenase activities known to be supported by P450 3A4/3A5, namely nifedipine oxidation (r = 0.78; N = 29); erythromycin N-demethylation (r = 0.69; N = 27), testosterone 6 beta-hydroxylation (r = 0.66; N = 25) and tamoxifen N-demethylation (r = 0.64; N = 29). On the other hand, E2-hydroxylations did not correlate with activities supported by P450 1A2 and P450 2E1. Furthermore, drugs as cyclosporin, diltiazem, triacetyl-oleandomycin and 17 alpha-ethynylestradiol inhibited more than 90% of the E2-hydroxylations at concentrations < 250 microM, while weak inhibition was shown with 500 microM cimetidine and no significant inhibition with
caffeine
, phenacetin and omeprazole. Finally, 2- and 4-hydroxylations of E2 correlated significantly with the content of P450 3A4/3A5 immunodetected by a monoclonal antibody anti-human P450-nifedipine (r = 0.84; N = 28). E2-hydroxylation activities were inhibited by more than 80% with polyclonal anti-human anti-P450-nifedipine. Preincubation of human liver microsomes with 100 microM gestodene (a suicide substrate of P450 3A4) inactivated this P450 isoform and accordingly allowed evaluation of the contribution of other P450 isoforms to the E2 metabolism to about 21% (+/- 17%, N = 29). All these results taken together suggest that P450 3A4/3A5 are the major forms involved in the formation of catecholestrogens in the human liver microsomes.
...
PMID:Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes. 144 32
Many drugs have been found to increase or decrease the clearance of theophylline, probably by interaction with one or more of the variants of the
cytochrome P450
drug-metabolising system. Theophylline may be particularly susceptible to alteration of its clearance because of the particular form(s) of the P450 system involved, because its metabolism is saturable, and/or because 90% of its elimination is via metabolism. Its clearance has been found to be decreased (typically by around 25%, but often by far more) by erythromycin, troleandomycin (triacetyloleandomycin), roxithromycin, enoxacin, ciprofloxacin, pefloxacin, norfloxacin, ofloxacin, fluoroquinolone T-3262, pipemidic acid, cimetidine, etintidine, propranolol, verapamil, diltiazem, nifedipine, furosemide (frusemide), at least some anovulent agents, viloxazine, allopurinol, ticlopidine, idrocilamide, thiabendazole, disulfiram, influenza- and BCG-vaccination, interferon, and
caffeine
(half-life increase). In contrast, theophylline clearance (clearance/bioavailability) was found to be increased by isoprenaline (isoproterenol), terbutaline, some corticosteroids, phenytoin, phenobarbital, activated charcoal, felodipine moricizine, benzodiazepines and sulfinpyrazone - typically by about 25%, but sometimes by as much as 80% or more. For several of these concomitant medications, however, only some of the published studies can substantiate an influence, which may highlight the sensitivity of some interactions to particular experimental and/or clinical conditions, e.g. with terbutaline, erythromycin, ciprofloxacin, norfloxacin, ofloxacin, phenobarbital, cimetidine, verapamil, diltiazem, nifedipine, anovulents, allopurinol and influenza vaccination. Moreover, reports both of inhibition and of induction of theophylline clearance by each of rifampicin and isoniazid have appeared. Nevertheless, under investigation many medications have not been found to perceptibly influence theophylline disposition kinetics, e.g. ephedrine, orciprenaline (metaproterenol), prednisone, prednisolone, temelastine, terfenadine, mequitazine, picumast, repirinast, josamycin, midecamycin, miocamycin, spiramycin, amoxicillin, ampicillin, cefalexin, cefaclor, ceftibuten, cotrimoxazole (trimethoprim plus sulfamethoxazole), tetracycline, doxycycline, lomefloxacin, fluoroquinolones NY-198 and AM-833, nalidixic acid, lincomycin, metronidazole, certain antacids, ranitidine, roxatidine, pirenzepine, rioprostil, metoclopramide, metoprolol, atenolol, nadolol, medroxyprogesterone, dextropropoxyphene (propoxyphene), piroxicam, ozagrel, mebendazole and ascorbic acid.(ABSTRACT TRUNCATED AT 400 WORDS)
...
PMID:Pharmacokinetic interactions between theophylline and other medication (Part I). 167 42
The activity of 7-ethoxycoumarin O-deethylase (ECOD) has been measured in liver biopsy samples from 23 patients (smokers and non-smokers) with different degrees of structural liver damage. The results, which reflect in vitro
cytochrome P450
-dependent biotransformation, were correlated with various measures of the P450-dependent in vivo elimination of
caffeine
and metamizol. The relatively non-specific, low affinity component of ECOD activity was significantly correlated with the kinetics of metamizol (mean residence time, apparent clearance, half-life, area under the concentration-time curve, and metabolite excretion in the urine). Thus, metamizol elimination, which is mainly due to P450 IIB, and the low affinity component of ECOD both reflect, at least in part, the activity of the same form of P450. In contrast,
caffeine
biotransformation, which is via P450 IA, was not correlated with ECOD activity. There was no relation between the kinetics of metamizol and
caffeine
, perhaps because of the inducing effect that smoking has on
caffeine
elimination. In patients with liver disease, smoking appears to alter the elimination of
caffeine
more than the degree of liver disease.
...
PMID:Comparison of in vitro and in vivo biotransformation in patients with liver disease of differing severity. 176 Oct 77
This review examines the literature on drug interactions with omeprazole. Different mechanisms have been proposed as potential causes for such interactions. First, the absorption of some drugs might be altered due to the decreased intragastric acidity resulting from omeprazole treatment. There was no effect of omeprazole on the absorption of amoxycillin, bacampicillin and alcohol, while the amount of digoxin and nifedipine absorbed was increased by 10 and 21%, respectively, both increases probably being of no clinical significance. Secondly, the metabolism of high clearance drugs might be altered by changes in liver blood flow, although that is not affected by omeprazole, as indicated by the unchanged elimination of indocyanine green. In addition, the clearance of intravenously administered lidocaine (lignocaine) [a high clearance drug] was unaffected by omeprazole, further indicating that the latter does not alter liver blood flow. Thirdly, since omeprazole is a substituted benzimidazole, it might have the potential to interfere with the metabolism of other drugs by altering the activity of drug metabolising enzymes in the
cytochrome P450
system, through either induction or inhibition. There is no indication of induction of this enzyme system in any interaction study with omeprazole. As regards inhibition, on the other hand, there is now considerable information available which indicates that omeprazole has the potential to partly inhibit the metabolism of drugs metabolised to a great extent by the
cytochrome P450
enzyme subfamily IIC (diazepam, phenytoin), but not of those metabolised by subfamilies IA (
caffeine
, theophylline), IID (metoprolol, propranolol) and IIIA (cyclosporin, lidocaine, quinidine). Since relatively few drugs are metabolised mainly by IIC compared with IID and IIIA, the potential for omeprazole to interfere with the metabolism of other drugs appears to be limited.
...
PMID:Omeprazole drug interaction studies. 176 70
This study was performed to investigate the possible influence of repeated omeprazole dosing on the metabolism of
caffeine
, which has been shown to reflect the activity of one specific enzyme within the hepatic
cytochrome P450
family, P450IA2. Ten healthy, nonsmoking young men participated in this placebo-controlled double-blind trial. Each subject was given omeprazole, 20 mg, every morning for 1 week and placebo every morning for 1 week in random order and separated by a 2-3 week washout period. On the sixth and seventh days of each period urine was collected twice daily, and urinary metabolites of
caffeine
were determined by high-performance liquid chromatography. The urinary metabolite ratio of three paraxanthine 7-demethylation products relative to a paraxanthine-hydroxylation product corresponds to
caffeine
clearance and, therefore, to P450IA2 activity. This calculated ratio was 4.8 (95% confidence interval, 3.9-5.6) in the placebo and 4.6 (95% confidence interval, 3.6-5.5) in the omeprazole period. These results show that the metabolism of
caffeine
was unaltered following omeprazole treatment, indicating that omeprazole treatment has no influence on cytochrome P450IA2 activity in the clinical situation.
...
PMID:Omeprazole treatment does not affect the metabolism of caffeine. 188 18
The time course in which the activities of
cytochrome P450
-dependent drug-metabolizing enzymes develop during the perinatal period differs for various types of monooxygenases as well as for various animal species. Using [3-methyl14C]-, [7-methyl14C]-
caffeine
, [14CH3]-methacetin and [14C2H5]-phenacetin as substrates in breath tests, the developmental changes in the rates of 14CO2 formation, due to changes in the activity of monooxygenases, were studied in rats and marmoset monkeys (Callithrix jacchus). In rats a rate of 0.006% of the dose administered/min was found to be exhaled as 14CO2 in the
caffeine
breath tests on the 1st day of life. This value increased gradually reaching adult rates of 14CO2 exhalation after 21 days for [3-methyl14C]-
caffeine
and after 25 days for [7-methyl14C]-
caffeine
. In marmosets the rate of 14CO2 exhalation for [3-methyl14C]- and [7-methyl14C]-
caffeine
was also low at birth and developed gradually reaching adult values of 14CO2 exhalation within 120-200 days. In rats the capacity for dealkylation of methacetin and phenacetin developed much faster compared with
caffeine
: 9 days postnatally, the exhalation of 14CO2 reached adult values. Offspring of marmosets reached adult values of 14CO2 exhalation at 8 days postnatally when using [14CO2]-methacetin as substrate and at 30 days postnatally using [14C2H5]-phenacetin in the breath test. The results suggest that the monooxygenases for the N-demethylation of
caffeine
, the O-demethylation of methacetin and the O-deethylation are rather substrate specific in the two species studied. The breath tests used are sensitive methods for assessing the development of different monooxygenases in vivo in rats and marmosets, and they may well (using 13C-labelled substrates) be applicable for studies in children to monitor effects of certain environmental pollutants.
...
PMID:CO2 breath tests using 14C-caffeine, 14C-methacetin and 14C-phenacetin for assessing postnatal development of monooxygenase activities in rats and marmosets. 191 90
Caffeine
was used as a metabolic probe to screen healthy subjects for their activities of two enzymes, deduced to be CYP1A2 (an inducible
cytochrome P450
) and xanthine oxidase. A longitudinal study revealed modest effects of
caffeine
dose, ethanol intake, and time-of-day on the CYP1A2 index, without any effect on the xanthine oxidase index. The coefficients of intraindividual variation not accounted for were 5.0% for the xanthine oxidase and 17.2% for the CYP1A2 index. In a population study, both indexes showed a log normal distribution, with CYP1A2 values of most subjects covering a 6.3-fold range but only a 1.7-fold range with xanthine oxidase. The CYP1A2 index was 33% decreased in women who used oral contraceptives and substantially increased in cigarette smokers. Neither the CYP1A2 nor the xanthine oxidase index differed between volunteers of Chinese and European extraction. Four of 178 subjects showed unexplained low xanthine oxidase values (i.e., values several standard deviations below the mean).
...
PMID:Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. 193 64
The activity of 3 enzymes related to the bioactivation of toxic compounds and the development of cancer--
cytochrome P450
IA2, N-acetyl transferase (NAT), and xanthine oxidase (XO)--can be measured from the ratios of formed metabolites excreted into urine. In the 3 experiments that comprised this study, subjects received at least 1 cup of coffee 2- 6 hours before spot urine samples were taken. The subjects included 335 healthy male and female volunteers who provided information on tobacco,
caffeine
, and broccoli intake in the preceding 2 weeks, 23 healthy men who exercised 8 hours/day for 30 days, and 9 subjects whose diet included green beans and broccoli. As expected, the ratio reflecting P450 IA2 activity was 66% and 70% higher, respectively, in men and women who smoked at least 10 cigarettes/day compared to male and female nonsmokers. The XO ratio also was significantly increased in smokers. 30 days of vigorous physical exercise increased the P450 IA2 ratio by 50% and the XO ratio by over 100%. Broccoli induced a 19% increase in P450 IA2 activity, while pregnancy and oral contraceptive use reduced this ratio by 29% and 20%, respectively. Since these ratios appear to yield reliable indicators of enzyme activity, prospective studies of their association with cancer development are recommended.
...
PMID:Cytochrome P450 IA2 activity in man measured by caffeine metabolism: effect of smoking, broccoli and exercise. 206 14
16 patients with different chronic liver diseases were given single doses of the model substances
caffeine
, metamizol, sufamethacine and debrisoquine. This was followed by the simultaneous administration of all these substances as a "cocktail". A comparison between the single and the "cocktail" dosage did not reveal any significant differences in the pharmacokinetic parameters. So the "cocktail" administration is even possible in chronic liver diseases. Requiring relatively little time, it makes statements possible concerning various
cytochrome P450
enzymes including the types of hydroxylation and acetylation. Intraindividual variations can be ruled out.
...
PMID:[Simultaneous administration of various model substances for characterizing in vivo biotransformation in chronic liver diseases]. 209 73
1
2
3
4
5
6
7
8
9
10
Next >>